Clinical Trial Update: A Randomized Neuroimaging Trial of Psilocybin in Depression [Phase 2]

View source ↗

Summary

A Phase 2 randomized neuroimaging trial evaluating psilocybin for depressive disorders, currently recruiting at Sunnybrook Health Sciences Centre.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorders
• Major Depressive Disorder

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Depressive Disorder, Major Depressive Disorder | Phase 2 | Status: RECRUITING